Aims: It remains controversial wether polymorphisms of the multidrug resistance gene ABCB1 are associated with pharmacoresistance in epilepsy. To furtehr study the potential association, we genotyped a broad set of tagging SNPs, and explored whether any associatios were affected by other host factors. We correlated any association with cerebral mRNA expression of ABCB1. Materials & methods: A total of 12 tagging and candidate SNPs of ABCB1 were genotyped in 464 Chinese epilepsy patients (270 drug responsive, 194 drug resistant). Genotype and allele distributions in drug-response and drug-resistant patients were compared. ABCB1 mRNA was quantified by real-time PCR in brain samples resected from 20 patients with drug-resistant epilepsy. Its l...
Background and Objective: Although pharmacoresistance is almost certainly due to several factors, th...
Alteration of ATP-binding cassette subfamily B member 1 transporter (ABCB1) can plausibly cause drug...
Approximately one third of newly treated epilepsy patients do not respond to antiepileptic drugs (AE...
There is accumulating evidence to suggest that overexpression of efflux drug transporters at the blo...
P-glycoprotein, the product of the ABCB1 gene, is a proposed mechanism of pharmacoresistance in epil...
Epilepsy constitutes a heterogeneous group of disorders that is characterized by recurrent unprovoke...
Objectives: The aim of this study was to investigate whether the polymorphisms in the NR112 and ABCB...
AbstractIt is proposed that overexpression of P-glycoprotein (P-gp), encoded by the ABC subfamily B ...
Objectives: The aim of this study was to investigate the association of the complex haplotype system...
Previous studies reported the associations between the ATP-binding cassette sub-family B member 1 (A...
Objectives The aim of this study was to investigate the association of the complex haplotype system ...
It is proposed that overexpression of P-glycoprotein (P-gp), encoded by the ABC subfamily B member 1...
Previous studies reported the associations between the ATP-binding cassette sub-family B member 1 (A...
Background: P-glycoprotein (P-gp), a drug efflux transporter, encoded by the gene MDR1 ABCB1 multidr...
Copyright © 2004 American Academy of NeurologyAlteration of ATP-binding cassette subfamily B member ...
Background and Objective: Although pharmacoresistance is almost certainly due to several factors, th...
Alteration of ATP-binding cassette subfamily B member 1 transporter (ABCB1) can plausibly cause drug...
Approximately one third of newly treated epilepsy patients do not respond to antiepileptic drugs (AE...
There is accumulating evidence to suggest that overexpression of efflux drug transporters at the blo...
P-glycoprotein, the product of the ABCB1 gene, is a proposed mechanism of pharmacoresistance in epil...
Epilepsy constitutes a heterogeneous group of disorders that is characterized by recurrent unprovoke...
Objectives: The aim of this study was to investigate whether the polymorphisms in the NR112 and ABCB...
AbstractIt is proposed that overexpression of P-glycoprotein (P-gp), encoded by the ABC subfamily B ...
Objectives: The aim of this study was to investigate the association of the complex haplotype system...
Previous studies reported the associations between the ATP-binding cassette sub-family B member 1 (A...
Objectives The aim of this study was to investigate the association of the complex haplotype system ...
It is proposed that overexpression of P-glycoprotein (P-gp), encoded by the ABC subfamily B member 1...
Previous studies reported the associations between the ATP-binding cassette sub-family B member 1 (A...
Background: P-glycoprotein (P-gp), a drug efflux transporter, encoded by the gene MDR1 ABCB1 multidr...
Copyright © 2004 American Academy of NeurologyAlteration of ATP-binding cassette subfamily B member ...
Background and Objective: Although pharmacoresistance is almost certainly due to several factors, th...
Alteration of ATP-binding cassette subfamily B member 1 transporter (ABCB1) can plausibly cause drug...
Approximately one third of newly treated epilepsy patients do not respond to antiepileptic drugs (AE...